# Ellenbarrie Industrial Gases I BUY

Earnings beat on faster ramp-up in Kurnool merchant ASU; reiterate BUY

Ellenbarrie Industrial Gases' (EIGL) standalone revenue was 3.6% higher than JMFe at INR 892mn in 2QFY26 (up 6.6% QoQ, but down 5.8% YoY on a high base as 2QFY25 revenue had one-off revenue of ~INR 150mn in the project engineering segment) led by higher gas revenue due to faster-than-expected ramp-up of its Kurnool merchant plant capacity utilisation and slight improvement in argon prices. Hence, EBITDA was also 4.8% higher than JMFe at INR 335mn while PAT was much higher than expected at INR 367mn, aided by higher other income (mostly due to interest on unused IPO proceeds) and lower taxes. The management said that Uluberia-2 ASU and East onsite plants are on track for Nov'25 and Mar'26 commissioning respectively while North India ASU completion has been delayed to 2HFY27 (vs. 2QFY27 earlier). We reiterate our BUY rating (unchanged TP of INR 550/share) based on 40x FY28E P/E as we expect EIGL to deliver a CAGR of ~30%/34%/32% in revenue/EBITDA/PAT over FY25-28, driven by 29% CAGR in merchant volume on account of strong capacity expansion and EBITDA margin improvement to 38% in FY28 (from 35% in FY25%) due to rise in proportion of revenue from high-margin argon.

- Revenue 3.6% higher than JMFe at INR 892mn, led by higher gas revenue though it was partly offset by lower project engineering segment revenue: Standalone revenue was 3.6% higher than JMFe at INR 892mn in 2QFY26 (up 6.6% QoQ, but down 5.8% YoY on a high base as 2QFY25 revenue had one-off revenue of ~INR 150mn in project engineering segment) led by higher gas revenue due to faster-than-expected ramp-up of its Kurnool merchant plant capacity utilisation (from 65% in 1QFY26 to 75-80% in 2QFY26) and slight improvement in argon prices. Gas revenue was 5.5% higher than JMFe at INR 879mn (up 8.7% QoQ and up 10.3% YoY), though it was slightly offset by lower project engineering segment revenue at INR 12mn (down 54.5% QoQ and down 91.7% YoY on a high base as there was one-off revenue of ~INR 150mn in 2QFY25).
- EBITDA also 4.8% higher than JMFe at INR 335mn while PAT much higher than expected at INR 367mn, aided by higher other income and lower taxes: Power expenses were also slightly higher at INR 184mn (up 4.5% QoQ but down 3.2% YoY) being 20.7% of revenue (vs. 21% of revenue in 1QFY26) and other expenses were higher at INR 224mn (up 13.7% QoQ and up 12.2% YoY). Hence, reported EBITDA was 4.8% higher than JMFe at INR 335mn (up 9.1% QoQ, but down 7.6% YoY on a high base as 2QFY25 EBITDA had one-off revenue of INR 150mn in the project engineering segment), leading to 84bps QoQ improvement in EBITDA margin to 37.5% in 2QFY26 (vs. 36.7% in 1QFY26). Further, PAT was significantly higher than JMFe at INR 367mn aided by higher other income (at INR 126mn vs JMFe of INR 70mn mostly due to interest on unused IPO proceeds) and lower tax expense (at INR 32mn vs. JMFe of INR 74mn).
- Repaid debt of INR 2.1bn using net IPO proceeds and kept unutilised IPO proceeds of INR 1.2bn in FDs; hence, net cash stood at INR 3.2bn at end-2QFY26: The company has utilised net IPO proceeds received from fresh issue of INR 3.7bn: a) repaid debt of INR 2.1bn (as proposed in prospectus); b) utilised INR 0.2bn on setting up of 220TPD Uluberia-Il merchant ASU (vs. INR 1bn proposed in prospectus; leaving INR 0.8bn unutilised at end-2QFY26); and c) utilised INR 0.15bn for general corporate purposes (vs. INR 0.55bn proposed in prospectus; leaving INR 0.4bn unutilised at end-2QFY26). Further, unutilised portion of IPO net proceeds of INR 1.2bn has been primarily held as fixed deposit and classified under Cash and cash equivalents. Hence, its gross debt declined to INR 1.1bn at end-2QFY26 (vs. INR 2.5bn at end-

1				
JM	Fin	an	cic	

Shivam Gupta

shivam.gupta@jmfl.com | Tel: (91 22) 66303082

Dayanand Mittal

dayanand.mittal@jmfl.com | Tel: (91 22) 66303063

Anupam Jakhotia

anupam.jakhotia@jmfl.com | Tel: (91 22) 69703686

Recommendation and Price Target						
Current Reco.	BUY					
Previous Reco.	BUY					
Current Price Target (12M)	550					
Upside/(Downside)	24.3%					
Previous Price Target	550					
Change	-0.1%					

Key Data – ELLEN IN	
Current Market Price	INR442
Market cap (bn)	INR62.3/US\$0.7
Free Float	21%
Shares in issue (mn)	140.9
Diluted share (mn)	140.9
3-mon avg daily val (mn)	INR129.0/US\$1.5
52-week range	638/430
Sensex/Nifty	84,467/25,876
INR/US\$	88.6

Price Performa	ance		
%	1M	6M	12M
Absolute	-0.7	0.0	0.0
Relative*	-3.0	0.0	0.0

\* To the BSE Sensex

Financial Summary					(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	2,695	3,125	4,010	5,322	6,802
Sales Growth (%)	31.4	16.0	28.3	32.7	27.8
EBITDA	615	1,097	1,462	2,027	2,615
EBITDA Margin (%)	22.8	35.1	36.5	38.1	38.4
Adjusted Net Profit	453	833	1,128	1,549	1,937
Diluted EPS (INR)	3.5	6.4	8.0	11.0	13.7
Diluted EPS Growth (%)	60.9	83.9	25.9	37.3	25.0
ROIC (%)	9.7	14.4	16.1	17.2	17.4
ROE (%)	11.7	18.4	15.3	14.7	15.8
P/E (x)	127.8	69.5	55.2	40.2	32.2
P/B (x)	14.1	11.7	6.4	5.5	4.7
EV/EBITDA (x)	101.3	57.2	40.3	29.5	22.9
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0

Source: Company data, JM Financial. Note: Valuations as of 12/Nov/2025

JM Financial Research is also available on: Bloomberg - JMFR <GO>, FactSet, LSEG and S&P Capital IQ.

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification.

FY25) while there was net cash (after reducing investment and Loans & Advances) of INR 3.2bn at end-2QFY26 (vs. net debt of INR 0.5bn at end-FY25). Further, cash capex was INR 542mn in 1HFY26 (vs. INR 489mn in 1HFY25).

- Uluberia-2 ASU and East onsite plant on track for Nov'25 and Mar'26 commissioning respectively; North India ASU completion delayed to 2HFY27 (vs. 2QFY27 earlier): The management reiterated that: a) Uluberia 2 (220TPD merchant plant in West Bengal) project will be operational by end-Nov'25 (expects full capacity utilisation in the next 18-24 months) and b) East onsite plant (320TPD onsite plant under construction) will be operational by Mar'26. Hence, it expects 2HFY26 to be better than 1HFY26. However, 220TPD merchant plant in North India, is now expected to be completed by 2HFY27 (earlier expected to be completed in 2QFY27). Hence, the management reiterated that its total plant capacity was 1,370TPD at end-FY25, and expects plant capacity to grow to 1,910TPD by end-FY26 and 2,130TPD by end-FY27 (excluding any new projects that could be announced later). Separately, the company is looking to build merchant capacity in West India and may come up with some related announcement soon.
- Reiterate BUY rating on EIGL with unchanged TP of INR 550: We reiterate BUY with unchanged TP of INR 550/share based on 40x FY28E P/E as we expect EIGL to deliver a CAGR of ~30%/34%/32% in revenue/EBITDA/PAT over FY25-28, driven by: a) 29% CAGR in merchant volume on account of strong capacity expansion; and b) EBITDA margin improvement to 38% in FY28 (from 35% in FY25% and 24% in FY24) due to rise in proportion of revenue from high-margin argon. At CMP, EIGL is trading at ~32x FY28 P/E and 23.8x FY28 EV/EBITDA. (vs. Linde India trading at valuation of ~54x FY28 P/E and 28.2x FY28 EV/EBITDA despite its EBITDA/PAT CAGR expectation being lower than EIGL with a similar RoE profile). Key risks: a) decline in price/volume of argon; b) lower volume growth due to delay in start of new capacity and/or slower ramp-up; c) high customer, industry and region concentration.

### 2QFY26 concall takeaways

1) Guided for gas segment revenue to grow at CAGR of 20-25% (on FY25 revenue base) and gas segment EBITDA margin to improve to ~40% over the next 4-5 years vs. 35% in FY25 and 37% in 1HFY26.

2) Reiterated that: a) Uluberia 2 (220TPD merchant plant in West Bengal) project will be operational by end-Nov'25 (expects full capacity utilisation in the next 18-24 months) and b) East onsite plant (320TPD onsite plant under construction) will be operational by Mar'26. Hence, expects 2HFY26 to be better than 1HFY26.

However, 220TPD merchant plant in North India is now expected to be completed by 2HFY27 (earlier expected to be completed in 2QFY27).

Reiterated that its total plant capacity was 1,370TPD at end-FY25, and expects plant capacity to grow to 1,910TPD by end-FY26 and 2,130TPD by end-FY27 (excluding any new projects that could be announced later).

- 3) Reiterated its focus on geographical expansion to become a pan-India player in the long term via organic and inorganic growth opportunities. It is looking to build merchant capacity in West India and may come up with some related announcement soon.
- 4) EBITDA margin expansion to 37.5% in 2QFY26 (vs 36.7% in 1QFY26) was due to: a) ramp-up in Kurnool merchant capacity to 75-80% in 2QFY26 (from 65% in 1QFY26); and b) rise in share of high margin argon to 13% of gas revenue in 2QFY26 (from 11% in 1QFY26), aided by QoQ improvement in argon prices. Earlier, the management had shared that it expects Kurnool merchant capacity utilisation to reach optimum level of 85-90% by 2HFY26.
- 5) Remains bullish on argon prices in the long term, as it expects its demand to grow much faster than its supply. It expects Argon's revenue contribution to inch up further from 13% in 2QFY26.
- 6) Gearing up to cater to demand for speciality gases in solar cell manufacturing and semiconductor industries (with initial focus on solar cell manufacturing industries). In discussions with a few of the solar cell manufacturers (already having a relationship with EIGL) for supply of required speciality gases.

Said that solar cell manufacturing requires various specialty gases like UHP nitrogen, UHP oxygen, UHP ammonia, etc. The company already has the capability to produce and supply UHP nitrogen and UHP oxygen while for remaining speciality gases (which it intends to import), it plans to set up a proper supply chain by building warehouses in its existing and upcoming facilities (requiring no additional land). It has even started working on such a warehouse in one of its facilities.

The margin on manufactured speciality gases will be higher than overall gas portfolio margin while traded speciality gases will have lower margin in range of 15-20%.

- 7) **Impact of recent GST rationalisation: a)** GST rate reduced on medical gases (liquid oxygen) from 12% to 5%; and **b)** GST rate unchanged for industrial gases.
- 8) Downplayed its focus on hydrogen by saying that it **doesn't foresee hydrogen as a meaningful revenue contributor, but** said it intends to build a hydrogen electrolyser alongside new ASUs in the future.

# 2QFY26 result review

Exhibit 1. Standalone quarterly snapshot							
(INR Mn)	1QFY25	2QFY25	4QFY25	1QFY26	2QFY26	% QoQ	% YoY
Net Sales	673	947	825	836	892	6.6%	-5.8%
Operating expenditure	454	585	579	529	557	5.2%	-4.8%
Cost of materials consumed	8	8	11	9	9	4.6%	6.0%
Purchase of stock-in-trade	65	127	104	78	104	32.6%	-18.5%
Decrease/ (Increase) in inventories	3	-2	5	6	-29	-552.1%	1110.1%
Staff expenses	49	62	55	63	65	3.3%	5.4%
Power expenses	187	191	197	176	184	4.5%	-3.2%
Administrative, O&M & Other expense	142	199	207	197	224	13.7%	12.2%
EBIDTA	219	362	246	307	335	9.1%	-7.6%
EBITDA Margin %	32.5%	38.2%	29.8%	36.7%	37.5%	84bps	-70bps
Depreciation	-49	-48	-65	-51	-51	-0.2%	5.6%
Interest	-39	-42	-54	-46	-11		
Other Income	79	72	114	68	126	84.7%	74.3%
Exceptional income/(expense)	0	0	0	0	0		
PBT	211	345	241	278	400	43.6%	15.8%
Tax	-49	-48	-59	-91	-32	-64.4%	-33.1%
PAT	162	297	182	187	367	96.2%	23.8%
EPS (INR)	1.2	2.3	1.4	1.3	2.6	96.2%	15.0%
Tax rate	23.2%	14.0%	24.3%	32.8%	8.1%		

Source: Company, JM Financial.

	1QFY25	2QFY25	4QFY25	1QFY26	2QFY26	% QoQ	% YoY
Segment Revenue (INR Mn)		-					
Gases, related products & services	658	797	795	809	879	8.7%	10.3%
Project Engineering	14	150	30	27	12	-54.5%	-91.7%
Total	673	947	825	836	892		
Segment Revenue Contribution (%)							
Gases, related products & services	98%	84%	96%	97%	99%		
Project Engineering	2%	16%	4%	3%	1%		
Total	100%	100%	100%	100%	100%		
Segment EBIT (INR Mn)							
Gases, related products & services	203	393	264	304	362	19.2%	-8.0%
Project Engineering	-1	118	-14	3	3	13.7%	-97.1%
Total	202	512	249	307	365		
Segment EBIT Margin (%)							
Gases, related products & services	30.9%	49.3%	33.2%	37.5%	41.2%		
Project Engineering	-6.0%	78.9%	-47.0%	11.0%	27.5%		
Segment Assets (INR Mn)							
Gases, related products & services	4,696	5,121	5,964	6,172	6,421		
Project Engineering	155	163	151	156	133		
Unallocated	2,259	2,498	2,345	10,816	4,906		
Total	7,110	7,782	8,460	17,145	11,460		
Segment Liabilities (INR Mn)							
Gases, related products & services	1,542	420	2,283	2,368	1,015		
Project Engineering	4	2	5	4	0		
Unallocated	1,303	2,775	1,238	5,652	1,227		
Total	2,849	3,197	3,526	8,024	2,242		

## **Assumptions and Estimates**

Exhibit 3. EIGL – Key operational a	ssumptions							
Particulars	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Key operational assumptions (bulk an	id packaged)							
Volume details								
Normal capacity (TPD)		378	378	500	624	675	829	1,040
Capacity utilisation (%)		96%	94%	75%	70%	84%	88%	92%
Production volume (TPD)		364	357	376	436	569	728	954
Sales Volume (TPD)		356	353	394	440	569	728	954
Realisation details (INR/scm)								
Oxygen		22.1	16.4	17.6	17.5	17.7	17.9	18.1
Nitrogen		11.9	12.6	12.8	13.5	13.9	14.3	14.8
Argon		82.9	71.5	120.4	119.7	70.0	73.5	77.2
Financials (INR Mn)								
Revenue	1,751	2,446	2,051	2,695	3,125	4,010	5,322	6,802
YoY Growth (%)	1%	40%	-16%	31%	16%	28%	33%	28%
Reported EBITDA	459	805	336	615	1,097	1,462	2,027	2,615
Reported EBITDA Margin (%)	26%	33%	16%	23%	35%	36%	38%	38%
EBITDA Growth YoY (%)	88%	75%	-58%	83%	78%	33%	39%	29%
OCF	709	314	387	437	43	2,057	1,206	1,635
Cash Capex	168	171	949	870	692	2,206	2,484	1,910
FCF	541	143	-562	-433	-649	-149	-1,278	-275
YoY Growth (%)	-37%	-74%	NM	NM	NM	NM	NM	-79%
Net Debt/(cash)	458	-895	-244	34	480	-3,386	-2,447	-2,512
Net Debt/Reported EBITDA (x)	1.0	-1.1	-0.7	0.1	0.4	-2.3	-1.2	-1.0

Source: Company, JM Financial.

Particulars	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Revenue break-up (INR Mn)							
Gases, related products & services	2,161	1,892	2,262	2,925	3,910	5,217	6,692
Onsite	51	51	99	457	552	775	788
Bulk and Packaged	2,110	1,841	2,162	2,464	3,358	4,442	5,904
Oxygen	1,191	801	936	1,024	1,628	2,323	3,174
Nitrogen	604	694	816	966	950	1,038	1,311
Argon	127	131	191	236	469	678	933
Other products	188	215	219	239	310	404	484
Project engineering services	285	158	433	200	100	105	110
Total	2,446	2,051	2,695	3,125	4,010	5,322	6,802
Revenue proportion (%)							
Gases, related products & services	88%	92%	84%	94%	98%	98%	98%
Onsite	2%	2%	4%	15%	14%	15%	12%
Bulk and Packaged	86%	90%	80%	79%	84%	83%	87%
Oxygen	49%	39%	35%	33%	41%	44%	47%
Nitrogen	25%	34%	30%	31%	24%	19%	19%
Argon	5%	6%	7%	8%	12%	13%	14%
Other products	8%	11%	8%	8%	8%	8%	7%
Project engineering services	12%	8%	16%	6%	2%	2%	2%
Total	100%	100%	100%	100%	100%	100%	100%
Revenue growth (%)							
Gases, related products & services		-12%	20%	29%	34%	33%	28%
Onsite		-1%	94%	362%	21%	40%	2%
Bulk and Packaged		-13%	17%	14%	36%	32%	33%
Oxygen		-33%	17%	9%	59%	43%	37%
Nitrogen		15%	18%	18%	-2%	9%	26%
Argon		3%	46%	23%	99%	45%	38%
Other products		15%	2%	9%	30%	30%	20%
Project engineering services		-44%	173%	-54%	-50%	5%	5%
Overall		-16%	31%	16%	28%	33%	28%

Exhibit 5. Consolidated EBITDA brea	Exhibit 5. Consolidated EBITDA breakup for EIGL								
Particulars	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E		
EBITDA break-up (INR Mn)									
Gases, related products & services	749	302	585	971	1,446	2,010	2,597		
Onsite	41	32	69	308	372	522	531		
Bulk and Packaged	708	270	516	663	1,074	1,488	2,066		
Project engineering services	56	35	30	126	16	17	18		
Total	805	337	615	1,097	1,462	2,027	2,615		
EBITDA proportion (%)									
Gases, related products & services	93%	90%	95%	89%	99%	99%	99%		
Onsite	5%	9%	11%	28%	25%	26%	20%		
Bulk and Packaged	88%	80%	84%	60%	73%	73%	79%		
Project engineering services	7%	10%	5%	11%	1%	1%	1%		
Total	100%	100%	100%	100%	100%	100%	100%		
EBITDA growth (%)									
Gases, related products & services		-60%	94%	66%	49%	39%	29%		
Onsite		-22%	116%	346%	21%	40%	2%		
Bulk and Packaged		-62%	91%	29%	62%	39%	39%		
Project engineering services		-38%	-14%	320%	-87%	5%	5%		
Overall		-58%	82%	78%	33%	39%	29%		
EBITDA margin (%)									
Gases, related products & services	35%	16%	26%	33%	37%	39%	39%		
Onsite	80%	63%	70%	67%	67%	67%	67%		
Bulk and Packaged	34%	15%	24%	27%	32%	34%	35%		
Project engineering services	20%	22%	7%	63%	16%	16%	16%		
Overall	33%	16%	23%	35%	36%	38%	38%		

Source: Company, JM Financial.

Particulars	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total sales volume (in ton p.a.)								
Oxygen	59,948	69,986	63,469	68,979	76,125	119,249	168,462	227,920
Nitrogen	62,436	57,484	62,477	72,329	81,219	77,614	82,274	100,942
Argon	4,131	2,468	2,945	2,558	3,174	10,798	14,874	19,509
Total	126,515	129,938	128,891	143,866	160,518	207,661	265,610	348,371
Average Selling Price (INR/SM3)								
Oxygen	16	22	16	18	17	18	18	18
Nitrogen	12	12	13	13	14	14	14	15
Argon	50	83	71	120	120	70	74	77
Sales (INR Mn)								
Oxygen	760	1,191	801	936	1,024	1,628	2,323	3,174
Nitrogen	654	604	694	816	966	950	1,038	1,311
Argon	127	127	131	191	236	469	678	933
Other products	0	188	215	219	239	310	404	484
Total	1,541	2,110	1,841	2,162	2,464	3,358	4,442	5,904
Sales volume proportion (%)								
Oxygen	47%	54%	49%	48%	47%	57%	63%	65%
Nitrogen	49%	44%	48%	50%	51%	37%	31%	29%
Argon	3.3%	1.9%	2.3%	1.8%	2.0%	5.2%	5.6%	5.6%
Total	100%	100%	100%	100%	100%	100%	100%	100%
Sales Value proportion (%)								
Oxygen	49%	56%	44%	43%	42%	48%	52%	54%
Nitrogen	42%	29%	38%	38%	39%	28%	23%	22%
Argon	8%	6%	7%	9%	10%	14%	15%	16%
Other products	0%	9%	12%	10%	10%	9%	9%	8%
Total	100%	100%	100%	100%	100%	100%	100%	100%


Exhibit 7. Change in estimates and TP								
	New	Old	Divergence					
TP (INR)	550	550	0.0%					
Rating	BUY	BUY						
Revenue (INR Mn)								
FY26	4,010	4,010	0.0%					
FY27	5,322	5,322	0.0%					
FY28	6,802	6,802	0.0%					
EBITDA (INR Mn)								
FY26	1,462	1,462	0.0%					
FY27	2,027	2,027	0.0%					
FY28	2,615	2,615	0.0%					
PAT (INR Mn)								
FY26	1,128	1,128	0.0%					
FY27	1,549	1,549	0.0%					
FY28	1,937	1,937	0.0%					
EPS (INR)								
FY26	8.0	8.0	0.0%					
FY27	11.0	11.0	0.0%					
FY28	13.7	13.7	0.0%					


Source: JM Financial

### **Valuation**

Exhibit 8. Valuation		
Particulars		
P/E multiple (x)	40.0	
FY28 EPS (INR/share)	13.7	
1-year TP (INR/share)	550	

Source: Company





Source: Company, JM Financial

		EV/EBI	TDA (x)		EBI	ITDA M	argins	(%)		P/E	(x)			P/B	(x)			ROE	(%)	
Company	FY25/	FY26/		FY28/		FY26/	FY27/	FY28/		FY26/		FY28/	FY25/	FY26/	FY27/	FY28/		FY26/	FY27/	
	CY24	CY25	CY26	CY27	CY24	CY25	CY26	CY27	CY24	CY25	CY26	CY27	CY24	CY25	CY26	CY27	CY24	CY25	CY26	CY27
Indian listed companies																				
Ellenbarrie (JMFe)	54.9	42.1	30.8	23.8	35.1	36.5	38.1	38.4	69.4	55.1	40.2	32.1	11.7	6.4	5.5	4.7	18.4	15.3	14.7	15.8
Linde India	63.8	56.2	34.2	28.2	29.0	33.4	34.7	35.3	107.7	100.8	67.7	54.3	13.1	11.9	10.2	8.5	12.7	12.3	19.0	20.3
Global listed companies																				
Linde PLC	17.4	16.7	15.7	14.7	37.8	39.4	39.9	40.3	27.0	26.0	23.9	21.9	5.2	5.1	4.8	4.7	16.9	19.5	20.3	23.6
Air Liquide	13.7	13.6	12.6	11.7	27.5	30.0	31.3	31.9	27.3	26.3	23.7	21.6	3.4	3.5	3.3	3.1	12.9	14.0	14.7	14.9
Air Products	13.2	15.2	14.1	13.2	49.9	41.8	43.4	44.0	24.9	21.9	20.2	18.8	3.9	3.4	3.2	2.9	24.4	16.0	16.6	16.6
Taiyo Nippon Sanso	9.9	9.4	8.9	8.5	22.8	23.8	24.0	24.4	20.6	18.2	17.0	16.0	2.2	2.0	1.9	1.7	11.1	11.7	11.3	11.2

# Financial Tables (Standalone)

Income Statement				(II	NR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	2,695	3,125	4,010	5,322	6,802
Sales Growth	31.4%	16.0%	28.3%	32.7%	27.8%
Other Operating Income	0	0	0	0	0
Total Revenue	2,695	3,125	4,010	5,322	6,802
Cost of Goods Sold/Op. Exp	549	357	397	480	568
Personnel Cost	161	228	229	297	377
Other Expenses	1,370	1,443	1,922	2,519	3,242
EBITDA	615	1,097	1,462	2,027	2,615
EBITDA Margin	22.8%	35.1%	36.5%	38.1%	38.4%
EBITDA Growth	83.2%	78.3%	33.2%	38.6%	29.0%
Depn. & Amort.	100	207	232	323	409
EBIT	515	890	1,230	1,704	2,206
Other Income	207	359	338	319	319
Finance Cost	80	171	108	16	17
PBT before Excep. & Forex	642	1,078	1,461	2,006	2,507
Excep. & Forex Inc./Loss(-)	0	0	0	0	C
PBT	642	1,078	1,461	2,006	2,507
Taxes	189	245	332	456	571
Extraordinary Inc./Loss(-)	0	0	0	0	C
Assoc. Profit/Min. Int.(-)	0	0	0	0	C
Reported Net Profit	453	833	1,128	1,549	1,937
Adjusted Net Profit	453	833	1,128	1,549	1,937
Net Margin	16.8%	26.7%	28.1%	29.1%	28.5%
Diluted Share Cap. (mn)	130.9	130.9	140.9	140.9	140.9
Diluted EPS (INR)	3.5	6.4	8.0	11.0	13.7
Diluted EPS Growth	60.9%	83.9%	25.9%	37.3%	25.0%
Total Dividend + Tax	0	0	0	0	C
Dividend Per Share (INR)	0.0	0.0	0.0	0.0	0.0

Balance Sheet					(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Shareholders' Fund	4,099	4,934	9,799	11,335	13,258
Share Capital	65	262	282	282	282
Reserves & Surplus	4,033	4,672	9,517	11,053	12,976
Preference Share Capital	0	0	0	0	0
Minority Interest	0	0	0	0	0
Total Loans	1,769	2,453	200	205	210
Def. Tax Liab. / Assets (-)	261	310	310	310	310
Total - Equity & Liab.	6,129	7,697	10,309	11,850	13,778
Net Fixed Assets	3,312	3,842	5,816	7,977	9,478
Gross Fixed Assets	4,562	4,840	7,046	9,530	11,440
Intangible Assets	0	0	0	0	0
Less: Depn. & Amort.	1,269	1,464	1,696	2,019	2,428
Capital WIP	19	466	466	466	466
Investments	1,725	1,971	2,749	2,585	2,585
Current Assets	1,688	2,646	2,578	2,213	2,741
Inventories	110	142	182	242	309
Sundry Debtors	453	826	1,060	1,407	1,798
Cash & Bank Balances	9	2	838	66	137
Loans & Advances	180	98	98	98	98
Other Current Assets	935	1,579	400	400	400
Current Liab. & Prov.	597	763	834	926	1,027
Current Liabilities	177	141	180	239	306
Provisions & Others	419	623	654	686	721
Net Current Assets	1,091	1,883	1,744	1,287	1,715
Total – Assets	6,129	7,697	10,309	11,850	13,778

Source: Company, JM Financial

(INR mn)

FY28E

2,507

<b>Cash Flow Statement</b>				
Y/E March	FY24A	FY25A	FY26E	FY27E
Profit before Tax	642	1,078	1,461	2,006
Depn. & Amort.	100	207	232	323
Net Interest Exp. / Inc. (-)	-73	-99	-230	-302
Inc (-) / Dec in WCap.	-172	-1,053	944	-348
0.11		17	17	17

D 0.4 .	100	207	222	222	400
Depn. & Amort.	100	207	232	323	409
Net Interest Exp. / Inc. (-)	-73	-99	-230	-302	-302
Inc (-) / Dec in WCap.	-172	-1,053	944	-348	-392
Others	1	-17	-17	-17	-17
Taxes Paid	-61	-74	-332	-456	-571
Operating Cash Flow	437	43	2,057	1,206	1,635
Capex	-870	-692	-2,206	-2,484	-1,910
Free Cash Flow	-433	-649	-149	-1,278	-275
Inc (-) / Dec in Investments	-511	-230	-777	163	0
Others	164	353	342	322	322
Investing Cash Flow	-1,217	-569	-2,641	-1,999	-1,587
Inc / Dec (-) in Capital	0	0	3,750	0	0
Dividend + Tax thereon	0	0	0	0	0
Inc / Dec (-) in Loans	758	684	-2,222	38	40
Others	-83	-165	-108	-16	-17
Financing Cash Flow	675	519	1,420	21	23
Inc / Dec (-) in Cash	-105	-7	836	-772	70
Opening Cash Balance	114	9	2	838	66

9

2

838

66

137

Source: Company, JM Financial

Closing Cash Balance

Dupont Analysis					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Margin	16.8%	26.7%	28.1%	29.1%	28.5%
Asset Turnover (x)	0.5	0.5	0.4	0.5	0.5
Leverage Factor (x)	1.4	1.5	1.2	1.0	1.0
RoE	11.7%	18.4%	15.3%	14.7%	15.8%
Key Ratios					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
BV/Share (INR)	31.3	37.7	69.5	80.4	94.1
ROIC	9.7%	14.4%	16.1%	17.2%	17.4%
ROE	11.7%	18.4%	15.3%	14.7%	15.8%
Net Debt/Equity (x)	0.0	0.1	-0.3	-0.2	-0.2
P/E (x)	127.8	69.5	55.2	40.2	32.2
P/B (x)	14.1	11.7	6.4	5.5	4.7
EV/EBITDA (x)	101.3	57.2	40.3	29.5	22.9
EV/Sales (x)	23.1	20.1	14.7	11.2	8.8
Debtor days	61	97	97	97	97
Inventory days	15	17	17	17	17
Creditor days	31	25	26	27	27

History of Recommendation and Target Price				
Date	Recommendation	Target Price	% Chg.	
13-Oct-25	Buy	550		

Recommend	

#### APPENDIX I

### JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com

Compliance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: ashley.johnson@jmfl.com Grievance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

New Rating Syster	New Rating System: Definition of ratings			
Rating	Rating Meaning			
BUY	Expected return >= 15% over the next twelve months.			
ADD	Expected return >= 5% and < 15% over the next twelve months.			
REDUCE	Expected return >= -10% and < 5% over the next twelve months.			
SELL	Expected return < -10% over the next twelve months.			

Note: For REITs (Real Estate Investment Trust) and InvIT (Infrastructure Investment Trust) total expected returns include dividends or DPU (distribution per unit)

Previous Rating System: Definition of ratings				
Rating	Meaning			
BUY	Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more than 15%			
БОТ	for all other stocks, over the next twelve months. Total expected return includes dividend yields.			
	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market			
HOLD	capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price			
	for all other stocks, over the next twelve months.			
SELL	Price expected to move downwards by more than 10% from the current market price over the next twelve months.			

<sup>\*</sup> REITs refers to Real Estate Investment Trusts.

#### Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### **Important Disclosures**

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions. Please click here to access our detailed Terms and Conditions, including the Most Important Terms and Conditions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., JM Financial Institutional Securities has an affiliate, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 27th Floor, Office No. 2715, New York, New York 10019. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.